Biotechnology Opportunities in New Zealand
February 2005
www.investnewzealand.govt.nz
Quick Facts - New Zealand
AREA (~ UK or Japan) 271,000 sq km POPULATION 4 million (60,000 Indian) Auckland 1.3 million (40,000 Indian) Wellington (Capital) 0.5 million Christchurch (South Island) 0.5 million Unemployment 3.8% Real GDP US$ 86 million GDP / capita US$21,500 CORPORATE TAX RATE 33.0% University Enrolments 450,000 Graduates 85,000
Investment NZ
• NZ Government investment attraction agency • Specialist unit within NZ Trade and Enterprise • Team of 40 professionals at 9 locations
Auckland & Wellington, New Zealand Sydney & Melbourne, Australia Singapore Hong Kong London, UK Los Angeles & New York, USA
Otherwise working through (48) NZTE offices
What we do
• Promote NZ value proposition in global markets • Support business strategies - increase the quality and quantity of investments - add value to the economy • Match international opportunities with NZ economic development needs
• Coordinate investment attraction/promotion activities acting as single point of government contact for foreign investors • Add value to NZ business through providing assistance and research advice, international alignment and focus, consistency and build networks and partnerships to facilitate foreign investment
How we assist companies
• Facilitation Cut through government red tape Introductions - Economic Development Agencies, Service providers, Companies, Regulatory authorities • Strategic Investment Fund (SIF) Projects over $50million 3 years or 200 new jobs Disbursed at INZ discretion Feasibility studies up to $100,000 for ½ costs • Visiting Investor Programme (VIP)
Biotech successes
• • • • • • • • Pharmacia (Pfizer) – Endocrinz (Neuren) PPL Therapeutics – farm GSK – Medical Research Institute NZ Birnie capital – Protemix Iglobe - Treasury VIF Roche and Genentech - Proacta Inventages – Life Sciences Ventures VIF Nupharm
AUCKLAND HAMILTON
PALMERSTON NORTH WELLINGTON NELSON
CHRISTCHURCH
DUNEDIN
New Zealand Biotechnology Sector Overview
• Government - key economic sector • 50+ companies, 8 Universities, 11 research institutes • Biomedical excellence in cancer, diabetes, immunology, neurological, metabolic disorders, nutrition, biomodels
• Leading technology underpinning agriculture and food production, health related foods and natural products • World’s best animal health rating for animal sourced bioproducts
• R&D history- animal/plant breeding, environmentally sustainable production.
• Glaxo of GSK founded in NZ; Wilkins - Nobel laureate DNA structure; Liggins – steroids for premature infants; Murdock - inventor disposable syringe
Supportive Environment
• Government is a strategic supporter of R&D - facilitation public/private partnerships
• Innovative, highest research standards =US, UK and Europe @50% cost
• Simple tax environment – No payroll, social security, capital gains or regional taxes
– R&D 100% tax deductible; depreciation on IP costs • High Standard Corporate Governance – Audits, high economic freedom, low corruption • Neutral foreign policy - seeking free trade agreements, IP protection – WIPO and Trips compliant
Opportunity Areas
• Healthcare – drug discovery, manufacture, clinical studies, biomedical research, bioprospecting, medical devices, health IT • Animal products (serum, proteins, enzymes & antibodies) disease-free, high security and traceability • Agbiotech – sheep, dairy, deer, pasture, fruit, crop and forestry – environmentally sustainable production of food & biomaterials, bioprocessing • Natural products, nutraceuticals & functional foods • Bioinformatics, structural biology, forensic services, waste treatment
Biopharmaceuticals - cardiovascular, type 2 diabetes and metabolic disorders.
Laszarin™, orally active small molecule, developed for diabetes related heart disease in Phase IIb trials. Preclinical peptide hormones for diabetes
CEO - Larry Ellingson (Eli Lilly / US Diabetes Assn) Founder, President, CTO - Prof Garth Cooper – University of Auckland, (Amylin) Chairman - Keith Mansford (GSK) Birnie Capital – series A $20m in 2003. USA - series B / licensing, partners other markets
www.protemix.co.nz
Cancer therapy – physiologically targeted drugs Low oxygen - hypoxic regions in solid tumors Broad portfolio of IP - 9 chemical families. Profs Bill Wilson & Bill Denny – University of Auckland, 15years experience - 6 drugs developed Collaboration with Professors Martin Brown & Amato Giacca - Stanford University CEO - Paul Cossum (NewBiotics, San Diego) Series A in 2004 $8million (Roche, Genentech, GBS Ventures, No8, Endeavour) for phase1 clinical trials
www.proactatherapeutics.com
Neuren pharmaceutical
Biopharmaceuticals - neuroprotection and repair, growth & metabolism regulation 5 patented families compounds - key indications for stroke, head injury, Parkinson’s, cognitive impairment, multiple sclerosis, and growth and metabolism disorders Lead Glypromate – phase 1
Professor Peter Gluckman (FRS) Liggins Institute, Auckland Partners Pfizer, Duke University (NC) Walter Reed Army (MD), University Texas and Metabolic Pharmaceuticals (Australia)
CEO David Clarke Listed ASX, - licensing, investment partners
www.neurenpharma.com
Biologics for inflammatory or atopic disorders - skin (psoriasis, dermatitis), lung (asthma), autoimmune (lupus), tuberculosis and cancer. Genomics based discovery and immunology - dendritic, T and B cells. Products: Zyrogen – lupus, YB1 – cancer, RNAi autoimmune
Listed NZX and ASX CEO Stephen Hall Founder Dr Jim Watson (ex University of Auckland) Product development partnerships
www.genesis.co.nz
CoDaTherapeutics
Wound healing – connexin protein targets - prevent lesion spread, inflammation and scarring to improve recovery. Patented antisense technology demonstrated in preclinical models - skin lesions, burns, cornea damage and spinal repair. Incorporate into wound dressings. Seeking strategic alliances, funding, licensing (specific indications or markets)
Professor Colin Green - University of Auckland and Dr David Becker University College London. CEO - Aki von Roy (former President BMS, Europe)
www.codatherapeutics.com
Cancer diagnosis and management - develop genetic based markers for rapid, accurate and non-invasive tests (serum, tumour, urine) Focus - Gastric, Bladder, Endrometrial, Colorectal cancers
Established - NZ Seed Fund (VC), listed NZX. Pharmaceutical and other partnerships
Professor Tony Reeve – University of Otago CEO David Darling
www.pacificedgebiotech.com
Living Cell Technology (LCT, Listed on ASX, research facilities in New Zealand, Australia, Italy and office US Encapsulated living cell products, treatment of Huntington's disease, haemophilia and insulin-dependent diabetes.
New Zealand: hosts worlds most advanced porcine herd therapeutic transplantation. Focused primarily early stage research & manufacture product pre-clinical and clinical studies, virology department set world standard for porcine cell characterization Products Portfolio include: NeurotrophinCell a choroid plexus cell product, Fac8Cell a liver cell product aimed at treating haemophilia, DiabeCell a porcine pancreatic cell product treatment insulin-dependent diabetes
www.lct.com.au
NZ manufacturer pharmaceuticals – skincare, arthritus, diabetes, cardiovacular, digestive, pain, sports, cosmetics, nasel, dietary.
Solid oral and liquid dose forms TGA (Australia), Ministry Health (NZ) MAF - licensed Marketing alliances and distribution – Pfizer, MSD, Ego, IBI, Nutricia, Serono, Eli Lilly, Solvay Duphar, Mundipharma Privately owned, 2 manufacturing sites, CEO - Graeme Douglas. Inquiries for manufacture, development and testing www.douglas.co.nz
HMG is part of the Australian based API group 2000 product lines: pharmaceuticals, natural products, beauty/toiletry products Develops, manufacture/ markets own products + contract manufacturing Markets including, Australia, North America, the UAE, Europe, Malaysia, Hong Kong, China, Taiwan, Korea and the Pacific Islands Australian Pharmaceuticals Industries recently announced shift manufacturing base from Sydney to Auckland Kim Campbell - CEO
www.psm.co.nz
NuPharm Laboratories – pharmaceutical development with contract services (formulation, clinical and stability batch manufacturing). Operating from Deeside, North Wales and Hamilton, New Zealand.
Provide flexible services full turnkey projects to individual projects. Steve Tickle and Will Gould
www.nupharmlabs.com
www.liggins.auckland.ac.nz
Biomedical and Clinical Research • • • • Pregnancy and Labour Fetus and Newborn Brain and Behaviour Growth Development and Aging
Established after Prof Mont Liggins – steroid use lung
development in premature infants
Profs Peter Gluckman and Jane Harding
Spin offs Neuren (Neuronz and Endocrinz) and Brainz
Auckland Cancer Society Research Centre
New drugs for cancer treatment Six compounds licensed / clinical trials Targets: Immature vasculature solid tumors Protein products of genes Improved cytotoxic drugs - more targeted / less toxic
Profs Bill Denny, Bill Wilson, Bruce Baguley
Spin off – Proacta Therapeutics
www.health.auckland.ac.nz/cancer/
Anatomical and biophysical - mathematical models for human physiology (genes – organs) Computer models for drug development - CellMLTM Computational bioengineering tools, platform development Collaboration – Physiome Project Founder Prof Peter Hunter
www.bioeng.auckland.ac.nz
Neurodegenerative diseases
Gene therapy (decoy and antisense DNA, peptide nucleic acids) neurotrophins for prevention neuronal death Stem cells brain and spinal cord – repair in response to injury
NZ neurological human brain bank – extensive collection
Molecular biology and anatomy of Huntington’s, Alzheimers, schizophrenia, Parkinson’s and epilepsy
Profs Richard Faull and Michael Dragunow
www.auckland.ac.nz
Human immune system - particular emphasis on T cells Developing new forms of therapeutic vaccines for cancer, particularly melanoma Leading synthetic chemists to design and produce novel formulations of vaccines capable of stimulating antigenspecific T cells, for pre-clinical testing in our lab using human tissue and cells.
Associate Professor Rod Dunbar
Cancer Genetics
Dissection - genetic events that lead to cancer
Wilms tumour - errors in genomic imprinting involved in tumourigenesis
Mutations in the E-Cadherin gene define a cancer syndrome known as hereditary diffuse gastric cancer, involved in early onset of gastric cancer in New Zealand families
Professor Anthony Reeve Spin Off: Pacific Edge Biotechnology Ltd
Biomedical research – Wellington Immunological Mechanisms of Asthma, Multiple Sclerosis, Cancer, Infectious Diseases (TB, RSV) Biodiscoveries group Mouse and rat colonies for cancer, asthma and neurological Collaboration Malaghan Institute and AgResearch
www.malaghan.co.nz
MOLECULAR MEDICINE AND PATHOLOGY
Focus - ways molecules regulate the human immune response in both normal and disease states
Bacterial and super-antigens Crystallizing superantigens with soluable MHC class II and T cell receptors, producing a transgenic mouse to study the superantigens function further and searching for novel superantigens Prof. John Fraser, Head of Medical Sciences
www.health.auckland.ac.nz/molmedpath
NEUROLOGICAL DISORDERS
www.auckland.ac.nz
Parkinsons Disease - development of novel genetic models of disease and investigation of the mechanisms underlying Parkinson’s neuropathology
FDA approval - world’s first human phase 1 clinical trial using a gene therapy approach for Parkinson’s disease. Prof. Matt During and Dr Deborah Young
STRUCTURAL BIOLOGY
Protein Structure and Function Part of international initiative – Mycobacterium, as cause of TB Bioinformatics, gene cloning and expression, protein purification and crystallization, 3D structural analysis by X-ray crystallography, and functional assay techniques to characterise potential new drug targets gaining a better understanding of the biology of this devastating human pathogen Prof. Ted Baker www.sbs.auckland.ac.nz
Phase I & II Clinical Trial Centres
Dr Richard Robson Phase I/II studies – Renal, other Roche established / other clients
Dr Shaun Holt Prof Richard Beasley Phase I/II – Respiratory, other GSK established / other clients
Medical Research Institute of NZ
Other Clinical Trials Groups
Epidemiology, biostatistics, project & data (IT) management clinical trials – heart, stroke, other
www.ctru.auckland.ac.nz
Beltas – CRO Services all phases, NZ regulatory. Focus European Biotechs www.beltas.com
Clinical schools – Auckland, Wellington, Christchurch, Dunedin
NZ’s leading medical device company Products: Respiratory humidification, Obstructive sleep apnea Neonate incubators Operating theatre (patient warmers, nerve stimulators) NZX & ASX listed
www.fphcare.com
Neonatal brain monitor for intensive care in premature infants – prevention of brain injury (Cerebral Palsy)
Developed by Professor Chris Williams, University of Auckland. BRM-2 brain monitor Owned by Tru-Test (NZX listed) CEO Dr Justin Vaughan Distrubution partners and investment
www.brainzinstruments.com
Biomatters creates software, to fill market-gaps in the biotechnology industry. Products ISEQ & Cheesecake ISEQ world’s first framework for integrating different data sources, while using “research agents” that update results as you are analysing
Creates order-of-magnitude time saving, cuts down supercomputing power required to run genome-genome analysis. www.biomatters.com www.reeltwo.com
Text mining tools solving some of hardest problems facing life Science researchers, bioinformaticists, IP analysts Products: Classifier, SureGene, SureChem, Entity Extractor NZ Centre of Excellence: Uni. Of Auckland/Agresearch Research areas: Genomics, Evolutionary Genomics, Conservation/Foresic Genetics, Genetic Epidemiology, Applied Bioinformatics, Application Dev.. www.bioinformatics.org.nz
(cGMP) certified manufacturer of natural biochemicals extracts from plant and animal raw materials. Products for pharmaceutical, dietary supplement, cosmetic, biotechnology, diagnostic and aquaculture uses.
Include - (plants) Actinidin, D-Pinitol, Echinacea extract and ProenOthera® (animal) bile derivatives - cholic acid, deoxycholic acid and dehydrocholic acid (and salts), cartilage extract including chondroitin sulphate and other glycosaminoglycans, proteins, peptones and thymus extracts.
Contact - Selwyn Yorke www.nzp.co.nz
www.richmond.co.nz
Serum, blood, other biologicals and organs from meat processing bovine, ovine, caprine, and cervine stock. Leading supplier of fetal calf serum. NZ accorded No. I status by the European Union in respect of BSE and related diseases
By-products an important business sector for Richmond
Richmond keen on partnerships to develop new product lines
Suppliers to Invitrogen and Hyclone
www.southpacificsera.co.nz
Animal blood products (serum and proteins) & custom made antibodies for use in therapeutic, cell culture, microbiology and immunology application Quality assured: produce products solely from donor sheep, cattle, goat
Products: SeraPac, HaemoPac, ImmonoPac, PlasPac Markets: Asia, Europe, North America
Symansis Ltd
Signalomics platform - drug development and disease diagnotics– establishing signal pathway targets using high activity polyclonal antibodies produced for commercial supply in sheep. Prof. Peter Sheppard
www.biodiscovery.co.nz
High through-put screening natural products from NZ terrestrial and marine microbes for control of Agriculture pests and diseases. Chemistry, protein analysis, toxicology and formulation Sensitive and highly miniaturised screens against a panel of agricultural test organisms representing a wide range of plant and animal pests and diseases
Advanced flow cytometric capability in plant and mammalian cellular physiology
Andrew Broadwell and Peter Wigley - Directors
www.agvax.co.nz
Business subsidiary of AgResearch R&D Develops, markets and distributes vaccines Animal health products for sheep, dairy/beef, deer, horses, pigs, dogs and cats
Other producers of animal vaccines in NZ include:
Animal health, animal welfare, biosecurity, conservation for sustainable pastoral farming productivity Research programmes: food safety & quality, spatial epidemiology, emerging diseases, wildlife health & conservation, reproductive management &diseases, locomotion & musculoskeletal rehabilitation, mycobacterial diseases, nutritional management animal production and diseases.
Cost-effective, integrative (pasture-to-plate) applied research to Internationally recognized quality standards (GLP) Primary Sponsor: Pfizer
Professor Grant Guilford www.ivabs.massey.ac.nz
www.fonterra.com
•World's largest exporter of dairy products
•13 billion litres of milk processed with 2 million tonnes of dairy products produced annually, 1,000 ingredient products to the international food industry
•Marketing & Innovation Group – Fonterra’s research and development group adding value to NZMP products.
•Subsidiary of Fonterra •Identification, discovery, commercialisation genes for improving milk production, composition, animal health, and pasture grasses •Interdependent platforms based around bovine and forage genomics
www.vialactia.com
Discovery bioactives from milk for human health Therapeutic & dietary products from milk for conditions osteoporosis, infectious diseases and various inflammatory disorders, including asthma, inflammatory bowel disease,diabetes, and atherosclerosis JV Fonterra & University of Auckland partners Seeks partnerships for development IP www.fonterra.com
Food and Food components affect health at the molecular Genetic level by using nutritional genomic methods 1st Target - Crohn’s disease Collaboration, Auckland Uni., Hortresearch, Agresearch and Crop & Food
Prof. Lyn Ferguson www.nutrigenomics.org.nz
Tatua Nutritionals division focused three key product areas– ingredients specialist nutrition, healthcare products; bionutrients customised biopharmaceutical applications Tatua Nutritionals’ specialty ingredients include spray dried milk proteins (caseinates, whey protein concentrates), protein hydrolysates and freeze dried biologically active proteins (lactoferrin and lactoperoxidase). Produces nutritional formulations, tablets and capsules containing bioactive ingredients.
Novel therapeutics and diagnostics proteins discovered from decades of sheep breeding Parasites and disease: lead candidates to control parasites and selected diseases in livestock species through genetic diagnostics, vaccines and novel anthelmintics Muscle development: increasing production in intensive livestock production systems extending to human diagnostic and therapeutic applications targeting muscle growth disorders Reproduction:products control mammalian fertility by increasing ovulation or inducing reversible sterilisation www.ovita.co.nz
BLIS - acronym for Bacteriocin like inhibitory substances natural antibacterial peptides/proteins for the control of Streptococcal throat infection, chronic bad breath, dental caries, ear and other infections. BLIS K12 product throat guard - based on S. salivarius and Salivarian B
Professor John Tagg, University Otago – 20 years R&D CEO Kelvin Moffat (ex Boots) Listed NZX. Licensing and distribution partners
www.blis.co.nz
Biotechnology company - production and marketing A2 MilkTM and milk products
Dr McLachlan correlation - A2 beta casein, natural milk protein variant with improved human health. Developed simple efficient (IP protected) means to incorporporate the protein in cows milk. CEO – Andrew Clarke. NZX listed. Licensing and distribution partnerships
www.a2corporation.com
Bioactive products for health and wellbeing Extracts - deer velvet antler, botanical (phytoeostrogens and antioxidants), animal (aprotinin) and marine oils
Aged related and womens health, sports recovery performance MAF and NZFSA certified - Free TSEs and Foot and Mouth disease CEO – Ross Keeley. AgResearch - key R&D provider Contracts, licensing and partnerships
www.bioproductsnz.com
Pure NZ colostrum (powder, capsule, tablets CEO Trevor Lock Distribution partners
www.purenz
Botanical compounds for health. Enzogenol products Safe antioxidant extract from pine bark Int’l sales. Private Co. Partnerships and investors. CEO Larry Stenswick www.enzo.nz
Canterbury and Nelson Nutraceuticals Cluster Botanical (Echinacea, red clover, mullein, St John’s wort, manuka oil,
valerian, hawthorne, alfalfa, horopito, wheat and barley grass)
Bee (propolis, pollen, venom, manuka honey) Marine (Greenshell mussel powder, shark cartilage, abolone powder,
pacific oyster powder, shark liver oil, omega 3 fish oil)
Other (deer velvet, hydroxyapatite, chondoitin sulphate, bovine cartilage,
glandular extracts, blood products, emu oil) Contract Manufacturing : private label, drying, grinding, freeze drying, milling, blending, bottling/ labeling, encapsulating, tableting Extraction - Water, Solvent, CO2, Alcohol, Countercurrent, Maceration, Cold Pressing, Contract growing and seed multiplication, Raw material suppliers, Research and Development/Consulting www.nutraceuticals.org.nz
Natural Product Cosmetics (all natural ingredients) Skincare, colours cosmetics, women’s and men’s, oils, balms, soaps, ache & pain relief, hair care, health supplements
•No synthetic preservatives [paraben free] •No harmful ingredients •Herbicide, pesticide and GM free •No animal ingredients or testing •Bioactive ingredients •Recycleable, reusable packaging Manuka oils, honey etc, scientific testing Distribution partnerships and joint ventures
www.livingnature.com
Apple, Kiwifruit, Berryfruit, Stonefruit New varieties and products Gene discovery: pest, disease and stress control, development, signalling, flavour, nutrition. Bioactives: nutrigenomics CRI formed 1992, 500 staff, R&D and commercial Partnerships www.hortresearch.co.nz
Biomaterials, Pine tree breeding, genetics, DNA markers, wood quality, Flowering control
www.forestresearch.co.nz
BioProcessing: Natural Products - identification, extraction and processing for cosmetic, health supplement and biochemicals
Biochemical technologies: carbohydrate chemistry, molecular structure analysis, separation technologies, organic natural product chemistry, chemical synthesis, fine chemicals, pharmaceuticals and agrochemicals
GlycoSyn small molecule cGMP synthesis Carbohydrate Chemistry: design, synthesis and characterisation IRL Biopharm manufacturing secondary metabolites for biotech and pharma.
CEO Nigel Kirkpatrick www.irl.cri.nz
Marine organisms Bio-actives
Biodiversity native animals and plants
Pharmaceutical, Forensic, Health, food, environment monitoring
Bio-prospecting extreme environments
Life Science Ventures – Venture Capital fund focus on life sciences in New Zealand and Australia
Agbiotechnology, Agriculture, Food Technology and Health
Partners: Direct Capital, Celentis, Inventages, Queensland State Bill Kermode
www.lifescienceventures.co.nz
iGlobe Treasury Fund - backed by New Zealand and Singapore governments - one of the four Venture Investment Funds (VIF). Tony Bishop www.iglobetreasury.com
Endeavour Capital - develop globally competitive companies based on science and technology innovations (biotechnology, software and medical sectors) Neville Jordan www.ecap.co.nz
No 8 Ventures – VIF technology fund Jenny Morel www.no8ventures.co.nz
NZ Investments
Dr Bret A M Morris Investment Manager - Biotechnology Investment New Zealand New Zealand Trade and Enterprise
bret.morris@investmentnz.govt.nz www.investnewzealand.govt.nz +64 9 919 9045